Cellyan Biotechnology Co., Ltd balance sheet HKPD

Annual Quarterly

As of Mar 31, 2025, Cellyan Biotechnology Co., Ltd had total assets of $9.4 million and total liabilities of $4.4 million. Stockholders' equity was $5.0 million. It held $748,721 in cash and investments against $2.4 million of total debt, net debt of $1.6 million. The current ratio, current assets divided by current liabilities, was 2.99.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line
FY 2025
Mar 31, 2025
Assets
Cash
1
Cash and investments
1
Receivables
5
Inventory
1
Total current assets
9
Property and equipment, net
0
Total assets
9
Liabilities and equity
Accounts payable
2
Total current liabilities
3
Total liabilities
4
Stockholders' equity
5
Debt
Debt due within a year
0
Long-term debt
2
Lease liabilities
0
Total debt
2
Net cash
-2
Ratios
Current ratio
2.99x
Debt to equity
0.48x
Return on equity
-0.54%
Return on assets
-0.29%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
Listed as
HKPD (Nasdaq)
Fiscal year ends
March 31
Incorporated in
Cayman Islands
Headquarters
Kowloon
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
2007702
Former names
Hong Kong Pharma Digital Technology Holdings Ltd (until Dec 17, 2025)

Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.